Evidence map›Paper›PMID 38388352›Full record

ArticleBMC infectious diseases2024

Global prevalence and burden of multidrug-resistant tuberculosis from 1990 to 2019.

Hengliang Lv, Xin Zhang, Xueli Zhang, Junzhu Bai, Shumeng You, Xuan Li, Shenlong Li, Yong Wang, Wenyi Zhang, Yuanyong Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hengliang Lv *Department of Epidemiology, School of Public Health, China Medical University, Shenyang, China.
Xin Zhang *Department of Epidemiology, School of Public Health, China Medical University, Shenyang, China.
Xueli Zhang *Changchun University of Chinese Medicine, Changchun, China.
Junzhu BaiDepartment of Epidemiology, School of Public Health, China Medical University, Shenyang, China.
Shumeng YouDepartment of Epidemiology, School of Public Health, China Medical University, Shenyang, China.
Xuan LiDepartment of Epidemiology, School of Public Health, China Medical University, Shenyang, China.
Shenlong LiChinese PLA Center for Disease Control and Prevention, Beijing, China.
Yong WangDepartment of Epidemiology, School of Public Health, China Medical University, Shenyang, China.
Wenyi ZhangDepartment of Epidemiology, School of Public Health, China Medical University, Shenyang, China. zwy0419@126.com.
Yuanyong XuDepartment of Epidemiology, School of Public Health, China Medical University, Shenyang, China. xyy_827@sina.com.

Funding

National Natural Science Foundation of China 2018ZX10713003
6 · The paper itself

Abstract

backgroundTuberculosis(TB) remains a pressing public health challenge, with multidrug-resistant tuberculosis (MDR-TB) emerging as a major threat. And healthcare authorities require reliable epidemiological evidence as a crucial reference to address this issue effectively. The aim was to offer a comprehensive epidemiological assessment of the global prevalence and burden of MDR-TB from 1990 to 2019.

methodsEstimates and 95% uncertainty intervals (UIs) for the age-standardized prevalence rate (ASPR), age-standardized incidence rate (ASIR), age-standardized disability-adjusted life years rate (ASR of DALYs), and age-standardized death rate (ASDR) of MDR-TB were obtained from the Global Burden of Disease (GBD) 2019 database. The prevalence and burden of MDR-TB in 2019 were illustrated in the population and regional distribution. Temporal trends were analyzed by using Joinpoint regression analysis to calculate the annual percentage change (APC), average annual percentage change (AAPC) and its 95% confidence interval(CI).

resultsThe estimates of the number of cases were 687,839(95% UIs: 365,512 to 1223,262), the ASPR were 8.26 per 100,000 (95%UIs: 4.61 to 15.20), the ASR of DALYs were 52.38 per 100,000 (95%UIs: 22.64 to 97.60) and the ASDR were 1.36 per 100,000 (95%UIs: 0.54 to 2.59) of MDR-TB at global in 2019. Substantial burden was observed in Africa and Southeast Asia. Males exhibited higher ASPR, ASR of DALYs, and ASDR than females across most age groups, with the burden of MDR-TB increasing with age. Additionally, significant increases were observed globally in the ASIR (AAPC = 5.8; 95%CI: 5.4 to 6.1; P < 0.001), ASPR (AAPC = 5.9; 95%CI: 5.4 to 6.4; P < 0.001), ASR of DALYs (AAPC = 4.6; 95%CI: 4.2 to 5.0; P < 0.001) and ASDR (AAPC = 4.4; 95%CI: 4.0 to 4.8; P < 0.001) of MDR-TB from 1990 to 2019.

conclusionsThis study underscored the persistent threat of drug-resistant tuberculosis to public health. It is imperative that countries and organizations worldwide take immediate and concerted action to implement measures aimed at significantly reducing the burden of TB.

Indexed as

Perinatal DeathTuberculosis, Multidrug-ResistantAfricaDatabases, FactualFemaleGlobal Burden of DiseaseGlycation End Products, AdvancedHumansMalePrevalenceGlycation End Products, AdvancedDisability-adjusted life yearsGlobalJoinpoint regressionMultidrug resistant tuberculosisPrevalence

Identifiers

PMID38388352
PMCPMC10885623

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.